top of page
.jpg)
NEW BOOK
LATEST NEWS
Biogen's Salanersen Shows Promise for SMA Patients Post-Gene Therapy
Biogen’s experimental drug, Salanersen, is showing promising potential for treating children with spinal muscular atrophy (SMA), even...
6 days ago
Sarepta Pauses Duchenne Gene Therapy Trial After Second Patient Death
Sarepta Therapeutics has temporarily halted its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys, after a second patient died...
6 days ago
Eli Lilly Acquires Verve Therapeutics to Enhance Cardiovascular Portfolio
Eli Lilly has acquired gene-editing startup Verve Therapeutics for approximately $1 billion, expanding its portfolio to include...
6 days ago
GENE TECH TIMES
The Future Has Arrived
Lenmeldy: The First FDA-Approved Gene Therapy for Metachromatic Leukodystrophy in Children
Lenmeldy , a groundbreaking gene therapy developed by Orchard Therapeutics , has recently received FDA approval , making it the first and...
Apr 15, 2024
bottom of page